Purple Biotech (TLV:PPBT), (NASDAQ:PPBT) is a biotechnology company focused on advancing various cancer therapies that target the challenges of resistance to treatments. With a pipeline that includes development-stage drugs aimed at providing new options for cancer patients, Purple Biotech's projects predominantly revolve around creating innovative, targeted therapies. The company's objective is to improve patient outcomes by exploring pathways and mechanisms that can overcome tumor resistance and reduce side effects, making cancer treatments more effective and tolerable. Purple Biotech is solely listed on the NASDAQ stock exchange under the symbol PPBT, highlighting its commitment to research and development in the oncology sector.